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a b s t r a c t
A systematic study was undertaken to gain more insight into the mechanism of transdermal delivery of
nanoencapsulated model dyes across microneedle (MN)-treated skin, a complex process not yet explored.
Rhodamine B (Rh B) and fluorescein isothiocyanate (FITC) as model hydrophilic and hydrophobic small/
medium-size molecules, respectively, were encapsulated in poly lactic-co-glycolic acid (PLGA) nanopar-
ticles (NPs) and delivered through full thickness porcine skin pretreated with MN array. Permeation
through MN-treated skin was affected by physicochemical characteristics of NPs and the encapsulated
dyes. Dye flux was enhanced by smaller particle size, hydrophilicity, and negative zeta potential of
NPs. Regarding encapsulated dyes, solubility at physiological pH and potential interaction with skin pro-
teins proved to outweigh molecular weight as determinants of skin permeation. Data were verified using
confocal laser scanning microscopy imaging. Findings coupled with the literature data are supportive of a
mechanism involving influx of NPs, particularly of smaller size, deep into MN-created channels, generat-
ing depot dye-rich reservoirs. Molecular diffusion of the released dye across viable skin layers proceeds at
a rate determined by its molecular characteristics. Data obtained provide mechanistic information of
importance to the development of formulation strategies for more effective intradermal and transdermal
MN-mediated delivery of nanoencapsulated therapeutic agents.
 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
1. Introduction
Transdermal delivery of drugs with unfavorable skin absorption
using microneedle (MN) array technology has the potential of
bringing to clinical practice more effective and safer products
[1–3]. By penetrating the skin in a minimally-invasive manner,
native or drug-loaded MNs create microchannels in the stratum
corneum (SC) and epidermis as in-skin pathways for drug diffusion.
This permits an increase in several orders of magnitude in the
passage or dermal targeting of drugs ranging from small
hydrophilic molecules such as alendronate [4] to macromolecules,
including low molecular weight heparins [5] insulin [6] and
vaccines [7,8].
While MN-mediated transdermal drug delivery has been exten-
sively investigated, the use of MN technology for transdermal
delivery of drug-loaded nanocarriers is novel [9–11]. An optimized
MN/drug-loaded nanocarrier transdermal delivery approach may
allow modulation of the absorption of the drug of interest [10].
For example, polymeric nanoparticles (NPs) offer a wide range of
benefits including in-skin drug targeting, control of skin perme-
ation, protection of the encapsulated drug from degradation in
the biological milieu in addition to reduced dose, and side effects
[12]. Drug release from NPs can be modulated by selectively mod-
ifying factors associated with shape, size, chemical composition,
internal morphology, surface charge, and use of combined enhanc-
ing strategies [13–15]. Without the use of physical methods of skin
permeation, the literature reports suggest that in most instances,
polymeric NPs penetrate the SC poorly [16,17] following passive
routes of permeation through the hair follicles where the drug is
released and transported to deeper skin layers [18,19]. Intuitively,
delivering NPs beyond the SC with the simultaneous creation of
additional larger and denser in-skin pathways would promote
translocation of NPs as drug-rich reservoirs deeper into the skin.
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A combined MN/nanoencapsulation approach has been reported
for the intradermal delivery of a nanoencapsulated lipophilic
model of a photosensitizer using dissolving MNs [11] and the
in vitro transdermal delivery of a rhodamine B (Rh B) as a model
medium-size dye using the poke and patch technique [10]. More
effective exploitation of the approach, however, should be based
on a better understanding of the variables controlling translocation
of NPs through the aqueous MN-created channels, particularly
those involved in in-skin drug release and the concentration
gradient-driven diffusion of the released encapsulated species
across hydrophilic, viable skin layers [20].
Confocal laser scanning microscopy (CLSM) indicated that
penetration and distribution of fluorescent polymeric NPs into
MN-treated skin are confined to the hair follicles and MN-created
channels in a size and concentration-dependent manner, with
significantly denser localization in the epidermis compared to
the dermis [21,22]. However, transdermal delivery of polymer
NPs across MN-treated skin has been a matter of controversy.
While polystyrene NPs applied to a MN-treated human epidermal
membrane reached receptor solutions in permeation experiments
[23,24], poly lactic-co-glycolic (PLGA) NPs could not permeate full
thickness human abdominal skin [22], murine [21], or porcine ear
skin [10].
In a recent study [10], we related MN characteristics and appli-
cation variables to the in vitro skin permeation of a nanoencapsu-
lated medium-size dye, Rh B, across MN-treated full thickness
porcine skin. In the present study, more insight into the mecha-
nism of MN-driven skin permeation of nanoencapsulated dyes as
model drugs was sought. The contribution of the carrier and encap-
sulated dye characteristics to MN-mediated skin permeation was
investigated using PLGA NPs with different physicochemical attri-
butes and Rh B and fluorescein isothiocyanate (FITC) as model
hydrophilic and hydrophobic molecules, respectively [25]. Both
dyes are easily determined spectrofluorometrically [26] and have
been widely used in fluorescence-based imaging applications
[19,27,28]. Further, the two dyes were used in an earlier report
[25] to examine possible correlation of molecular characteristics
with passive diffusion and MN-mediated permeation through full
thickness porcine skin.
2. Material and methods
2.1. Chemicals
Poly lactic-co-glycolic acid (PLGA), Resomer RG 503 H (50:50)
(MW 24,000–38,000 Da), and Resomer RG 753 S (75:25) (MW
36,610 Da) both of inherent viscosity of 0.32–0.44 dl/g in 0.1%
in chloroform at 25 C and Polylactic acid (PLA) Resomer R 203
H (MW 18,000–28,000 Da) of inherent viscosity 0.25–0.35 dl/g
were purchased from Boehringer Ingelheim (Ingelheim, Ger-
many). Rhodamine B (Rh B, MW 479.02 Da), fluorescein isothiocy-
anate (FITC, MW 389.38 Da), Didodecyldimethyl ammonium
bromide (DMAB), Polyvinyl alcohol (PVA, MW 30–70 kDa), and
phosphate buffer saline (PBS) tablets (pH 7.4) were obtained from
Sigma–Aldrich (St. Louis, MO, USA). Ethyl acetate, AR grade (Fish-
er Scientific UK Ltd., Loughborough, UK), Nanovan, methylamine
vanadate stain (Nanoprobes, Nanophank, NY, USA) ‘‘Silver dag’’ –
a colloidal silver preparation – (Polysciences Inc., Eppelheim, Ger-
many) and Silastic 9280/60E silicone elastomer (Dow Corning,
Midland, MI, USA) were also used. Gantrez AN-139, a copolymer
of methylvinylether and maleic anhydride (PMVE/MA), was a gift
provided by Ashland (Waterfield Tadworth Surrey, KT20 5HQ,
UK). Shandon M-1 embedding OCT (optimal cutting temperature)
matrix was purchased from Thermo Electron Corporation (Been-
ham, Reading, UK).
2.2. Preparation and characterization of Rh B and FITC-loaded PLGA
nanoparticles
2.2.1 Preparation of nanoparticles (NPs)
NPs were prepared using a modified emulsion–diffusion–evap-
oration method used in an earlier study where reproducibility of
dye content, size, and surface charge of Rh B-loaded PLGA NPs
has been demonstrated using triplicate experiments [10]. In brief,
50 mg of polymer was dissolved in 2.5 mL ethyl acetate for 2 h at
ambient temperature using a magnetic stirrer (Cimarec i Poly 15
Multipoint stirrer, Thermo Electron Corporation, Beenham, Read-
ing, UK). For the preparation of Rh B-loaded NPs, a 200 lL aliquot
of an aqueous Rh B solution of specified concentration was emulsi-
fied in the organic phase for 5 min using a high speed homogenizer
(Polytron PT4000, Littau, Switzerland) to produce a w/o emulsion.
An aqueous DMAB solution (5 mL) of specified concentration was
added to the resulting emulsion under stirring to produce a w/o/
w emulsion. This was followed by homogenization for 5 min. The
resulting emulsion was diluted with 25 mL of water with constant
stirring. For FITC-loaded NPs, specified weights of the dye were dis-
solved in the polymer solution prior to the addition of either PVA
or DMAB solution of specified concentration, followed by a single
homogenization step to yield an o/w emulsion. This was diluted
with water (25 mL) and stirred to allow solvent evaporation.
Selected formulation variables and the emulsion homogeniza-
tion speed were modulated to generate dye-loaded PLGA NPs with
different physicochemical characteristics (NPs size, hydrophilicity,
surface charge, dye type, and dye initial loading). NPs size was
modified by controlling the emulsion homogenization speed
(5000, 10,000 and 15,000 rpm), while NPs hydrophilicity was mod-
ulated using PLGA copolymer with different lactic to glycolic acid
ratios (50:50, 75:25, 100:0). The type of NPs surface charge was
determined by the emulsion stabilizer used. DMAB resulted in pos-
itively charged NPs, while PVA produced negatively charged NPs.
The dye loading of NPs dispersions with Rh B and FITC was in-
creased by adjusting the initial loading (5%, 10%, and 20% w/w)
during emulsification. Unless otherwise mentioned, all experi-
ments were conducted by varying one parameter while keeping
other parameters set at selected conditions. Table 1 shows the test
dye-loaded NP formulations obtained by modulating formulation
variables and homogenization speed.
2.2.2. Transmission electron microscopy (TEM) of NPs
The morphology of NPs was examined by transmission electron
microscopy (TEM) (LEO 912 AB Omega, Zeiss, Oberkochen, Ger-
many). A 50 lL volume of diluted NP dispersion (1:10) was placed
onto the surface of a formvar/carbon coated 300 mesh grid and al-
lowed to settle for 30 s. Excess sample was drained from the grid
by touching the edge with a filter paper. A 5 lL volume of Nano-
van was then added to the sample and removed immediately
afterward. The grids were left to dry and examined using TEM.
2.2.3. Determination of the size and zeta potential of NPs
The size and size distribution (polydispersity index, PDI) of the
NPs was determined by photon correlation spectroscopy using a
Zetasizer (Nano ZS dynamic light scattering instrument, Malvern
Instruments Ltd., Malvern, UK). Each sample was run five times.
The same instrument was used to determine the zeta potential val-
ues of the NPs dispersed in distilled water. Each determination rep-
resented a mean value derived from 30 replicate measurements.
2.2.4. Determination of Rh B and FITC content of NPs dispersions
The fluorescence of NP dispersion samples diluted with PBS
(pH 7.4) was determined by fluorescence spectrophotometry as
reported [26]. The fluorescence intensity of a 300-fold diluted
translucent sample of the prepared NP dispersion was measured
146 Y.A. Gomaa et al. / European Journal of Pharmaceutics and Biopharmaceutics 86 (2014) 145–155
using a Varian Cary Eclipse fluorescence spectrophotometer (Var-
ian Australia Pty Ltd., Mulgrave, Victoria, Australia). The excita-
tion/emission wavelengths were set to 540/625 and 495/525 nm
for Rh B and FITC, respectively.
2.2.5. In vitro release of Rh B NPs
A 500 lL-sample of Rh B NPs dispersions of different PLGA com-
position (F3, F4 and F5) was placed in 1 mL ready-to-use dialysis
devices (Float-A-Lyzer G2, 20 kDa MWCO, Spectra/Por, USA).
Prior to use, the screw caps were removed, and the devices were
submerged open and allowed to soak in deionized water for
30 min to remove the impregnating glycerol added by the manu-
facturer for protection. The devices were allowed to float vertically
using the floatation rings at 37 C in a 10 mL-beaker containing
8 mL of PBS pH 7.4, selected to correlate release data with skin per-
meation data. The release medium was stirred using small mag-
netic bars at 500 rpm and a multipoint magnetic stirrer (Cimarec
i Poly 15 Multipoint stirrer, Thermo Electron Corporation, Been-
ham, Reading, UK). Samples (100 lL each) were removed from
the beakers at specified time intervals for up to 6 h. An equal vol-
ume of fresh PBS (pH 7.4) was added to maintain a constant vol-
ume. The withdrawn samples were analyzed by fluorescence
spectroscopy as described earlier.
2.3. Fabrication and imaging of microneedle (MN) arrays
MN arrays were fabricated using 30% w/v aqueous polymeric
solution of PMVE/MA copolymer and laser-engineered silicone
micro-molding, as described previously [29,30]. For scanning
electron microscopy (SEM) imaging, arrays were mounted on
aluminum stubs using double-sided adhesive tape and ‘‘silver
dag.’’ A SC515 SEM sputter coater (Polaron, East Grinstead, UK)
was used to coat the arrays with a 20 nm-thick layer of gold/palla-
dium. The arrays were observed under a JSM 6400 digital SEM
(JEOL Ltd., Tokyo, Japan), and photomicrographs of MN structures
were obtained.
2.4. In vitro skin permeation studies
Full thickness porcine skin was obtained from ears of pigs
(Landrace species), harvested immediately following slaughter at
a local abattoir (Glasgow, UK). The ears were sectioned using a
scalpel to yield whole skin samples. The average thickness of skin
samples, as measured using a digital micrometer, was
1164 ± 103 lm (n = 46). MN arrays of 600 lm length, 121 MNs/ar-
ray in density (11  11) were manually pressed onto the center of
each skin sample five times, and MN arrays were rotated  90
before each re-insertion. The last insertion of the MN lasted 2 s be-
fore retraction of the array. The MN-treated skin samples were in-
serted as barrier membranes in the Franz diffusion cells
(PermeGear, Bethlehem, PA, USA). These were attached to thermo-
statically-modulated water pump (Haake DC10, Karlsruhe, Ger-
many). The receiver cells contained 5.3 mL PBS (pH 7.4), which
was stirred at 600 rpm and maintained at 37 ± 0.5 C. Skin samples
were initially left in the Franz cells for 1 h to allow for hydration.
The permeation experiment was started by adding a 500 lL aliquot
of test NP formulation onto each skin sample. The dye content of
test NP formulations was adjusted to 77.5 lg/mL by diluting the fi-
nal NP dispersion with distilled water [26] leading to a constant
dye content but variable NP concentration. The effect of NPs size,
PLGA copolymer ratio, surface charge, dye type, and % of initial
dye loading on in vitro permeation through MN-treated porcine
skin was investigated. FITC NPs with positive and negative zeta po-
tential were used to test the effect of surface charge on skin perme-
ation of the nanoencapsulated dye.
In all cases, a 100 lL-sample was removed from the sampling
arm at specific intervals over 48 h, while an equal volume of fresh
PBS was added to maintain a constant volume. The withdrawn
samples were analyzed by fluorescence spectroscopy as mentioned
earlier taking into account the progressive dilution of the receiver
phase occurring over the course of the experiment. The cumulative
amount of dye permeating through the skin was plotted as a func-
tion of time. The steady state flux was calculated as the slope of the
linear portion of their time permeation profile divided by the diffu-
sional area (0.64 cm2) of the skin sample. Data presented are the
mean of at least three experiments.
2.5. Confocal laser scanning microscopy (CLSM)
At the end of the permeation experiment, skin samples exposed
to Rh B NPs (F7) and FITC NPs (F10) were collected and the SC
cleaned thoroughly under running cold water then blotted dry
with soft tissue. For viewing vertical skin sections, skin was
embedded in OCT medium and cryo-sectioned to 10 lm-thick ver-
tical sections using a Shandon Cryotome (SME Cryostat, Fisher
Thermo Scientific, Asheville, NC, USA). Same sectioning technique
was used in order to obtain relative results. Transmission images
of the skin were recorded using a Leica TCSP5 confocal microscope
connected to a DM6000B upright microscope (Leica Microsystems
GmbH, Wetzlar, Germany) with an HCX-APO-L-U-V-1 20 0.5
water dipping objective in case of Z-stacks of full thickness or a
20 Leica HC.PL. Fluotar (dry) objective (0.5 NA) in case of vertical
skin sections. Excitation was provided by a 514 nm (Rh B NPs, F7)
and 488 nm (FITC NPs, F10) Argon laser (20 mW) line with filtered-
Table 1
Formulation variables and pharmaceutical attributes of PLGA NPs prepared using an emulsion–diffusion–evaporation method.
Dye Formula code NPs formulation variables Homogenization speed, rpm NPs properties, mean ± SD (nP 5)
PLGA composition Dye
(% w/w)
DMAB
(% w/v)
PVA
(% w/v)
Size
(nm)
PDI Zeta potential
(mV)
Rh B F1 50:50 20 3 – 5000 422.3 ± 5.52 0.37 ± 0.04 65.7 ± 1.53
F2 50:50 20 3 – 10,000 251.5 ± 7.80 0.67 ± 0.06 67.6 ± 1.19
F3 50:50 20 3 – 15,000 155.2 ± 4.73 0.48 ± 0.02 66.4 ± 1.51
F4 100:0 20 1 – 15,000 91.90 ± 2.47 0.17 ± 0.01 54.7 ± 2.37
F5 75:25 20 1 – 15,000 101.1 ± 2.90 0.15 ± 0.02 50.4 ± 1.52
F6 50:50 20 1 – 15,000 105.5 ± 2.92 0.15 ± 0.02 55.2 ± 2.86
F7 50:50 10 1 – 15,000 117.4 ± 0.94 0.16 ± 0.01 57.0 ± 1.21
F8 50:50 5 1 – 15,000 121.7 ± 3.13 0.15 ± 0.02 54.1 ± 1.44
FITC F9 50:50 5 1 – 15,000 130.9 ± 4.85 0.16 ± 0.01 66.1 ± 2.28
F10 50:50 10 1 – 15,000 122.0 ± 3.15 0.15 ± 0.02 57.1 ± 1.51
F11 50:50 20 1 – 15,000 362.7 ± 78.48 0.67 ± 0.04 36.1 ± 2.09
F12 50:50 10 – 1 15,000 367.0 ± 22.46 0.41 ± 0.05 4.5 ± 0.45
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base emission channels of 565–625 nm (F7) and 491–567 nm
(F10). X–Z sectioning was performed to detect dye depth of pene-
tration. For viewing Z-stacks of full skin thickness, the Z-axis
images were gathered at 10 lm planes to a total depth of
200 lm using the 543 nm Argon laser line set to 40% of output.
The frame size was set to 1024  1024 pixels, and the image was
composed of 3 frames. Gain and offset were maximized to enhance
contrast. Subsequent image visualization was performed using
High Performance 3D–4D imaging software (Volocity 5.5, Improvi-
sion). The depth of the microchannels was estimated indirectly
based on the depth of dye permeation.
2.6. Statistical analysis
Where appropriate, a Mann–Whitney U or a Kruskal–Wallis test
followed by a post hoc Dunn’s test was used to analyze permeation
data using SPSS software (SPSS Inc., Chicago, IL, USA). In all cases,
P 6 0.05 denoted significance.
3. Results
The study involved assessment of the effect of characteristics of
PLGA NPs (size, hydrophilicity, and charge) and dyes encapsulated
therein (molecular weight, solubility, and % initial loading) on skin
permeation using the dual MN/nanoencapsulation approach. The
structures of the two dyes used in the study (Rh B and FITC) are
shown in Fig. 1. At physiological pH, Rh B is zwitterionic with a
net neutral charge, while FITC is anionic [25]. The design of poly-
mer MN arrays and application mode used in this study was based
on data reported earlier for the effect of MN characteristics on
in vitro skin permeation of nanoencapsulated Rh B [10]. As shown
in Fig. 2, MNs were conical in shape, with an average basal width of
300 lm, an average length of 600 lm and arranged at an inter-nee-
dle spacing of 300 lm with a density of 121 MNs per array.
3.1. PLGA NPs with different physicochemical characteristics
PLGA NPs with controlled physicochemical properties were pre-
pared using 2% w/v polymer and an emulsion–solvent evaporation
method [10] with modulation of formulation variables and homog-
enization speeds (Table 1). The variable levels were optimized in
order to modulate a target property without appreciably affecting
other dependent properties. A total of eight Rh B and four FITC test
NP formulations were used (Table 1). NPs prepared with DMAB
(F1–F11) had a positive zeta potential due to adsorption of the cat-
ionic emulsion stabilizer, while those prepared with PVA (F12) had
a negative surface charge conferred by the free end carboxylic
groups of PLGA. Positive zeta potential values were generally great-
er than 30 mV.
Table 1 shows that Rh B-loaded PLGA 50:50 NPs (F1–F3) with
different size (422.3–155.2 nm) could be obtained using 3% w/v
DMAB by increasing emulsion homogenization speed while keep-
ing other formulation variables constant. Further, modulation of
NPs hydrophilicity (F4–F6) was achieved by using PLGA with dif-
ferent lactide to glycolide ratio (100:0, 75:25, and 50:50) without
discernibly affecting particle size, PDI, and zeta potential of NPs.
The table also shows that PLGA 50:50 NPs could be loaded with
Rh B at increasing levels (5%, 10%, and 20% w/w, F6–F8) with no
detectable effect on particle size, PDI, and zeta potential values.
However, increasing FITC loading (F9–F11) particularly at the
20% w/w level was associated with a marked increase in particle
size and PDI and reduced zeta potential. The FITC NPs formulation
(F12) prepared using 1% w/v PVA as stabilizer showed a zeta poten-
tial of 4.5 and a distinct increase in particle size.
Fig. 3 shows TEM images of representative Rh B (F8) and FITC
(F9) NPs samples prepared using PLGA 50:50 at 5% w/w dye load-
ing. NPs were spherical in shape with more or less uniform size
verifying size data presented in Table 1.
3.2. In vitro skin permeation studies
Data for skin permeation of nanoencapsulated dyes across MN-
treated porcine ear skin, expressed as cumulative amount of dye
permeating at 48 h (Q48, lg/cm
2) and steady state flux (lg/cm2/
h), are presented in Table 2. Several reports provided evidence
for maintenance of the barrier function of porcine skin for up to
48 h [10,31]. Further, frequent sampling was essential for the ini-
tial part of the study due to the lack of the literature data regarding
the permeation of a dye loaded into nanoparticles through
MN-treated skin.
3.2.1. Effect of NPs-related variables on skin permeation of the
nanoencapsulated dye
3.2.1.1. Effect of NPs size. At the 1% w/v DMAB concentration used
throughout the study, NPs had a mean diameter of approximately
100 nm (Table 1) which did not noticeably change in response to
homogenization speed (screening data not shown). The higher con-
centrated 3% w/v DMAB solution had a higher viscosity
(20.8 ± 0.0026 cP) as measured using a cone and plate viscometer
(CSL2 100, TA Instruments, Crawley, UK) compared to that of the
1% w/v solution (3.71 ± 0.0004 cP). It resulted in a measurable in-
crease in particle size that was inversely proportional to the
homogenization speed. Thus, NP size was controlled by optimizing
emulsion homogenization speed and DMAB concentration (Table
1). The increase in particle size of Rh B-loaded PLGA 50:50 NPs sig-
nificantly (P < 0.05) reduced Rh B skin permeation (Fig. 4) despite
the PDI values exceeding 0.2. Mean Q48 values of 2.49 ± 0.08,
2.02 ± 0.11 and 0.5 ± 0.20 lg/cm2 and flux values of 3.55 ± 0.09,
2.83 ± 0.19 and 0.81 ± 0.28 lg/cm2/h were obtained for test NPs
formulations F1 (155.2 nm), F2 (251.5 nm) and F3 (422.3 nm),
respectively.
3.2.1.2. Effect of NPs polymer composition and hydrophilicity. The in-
crease in hydrophilicity of Rh B-loaded PLGA NPs (F4–F6) of more
or less similar size (91.9–105.5 nm), achieved by reducing lactide
to glycolide ratio, enhanced dye permeation across MN-treated
skin (Fig. 5). Data in Table 2 indicated that exposure of skin sam-
ples to F4 NPs (PLGA 100:0) resulted in a mean Q48 of
2.07 ± 0.19 lg/cm2 and flux of 2.90 ± 0.27 lg/cm2/h. Reducing the
lactide to glycolide ratio to 75:25 (F5) increased Q48
(2.92 ± 1.32 lg/cm2) and the flux (3.98 ± 1.62 lg/cm2/h) yet not
significantly (P = 0.379, 0.395, respectively). A further reduction
in the lactide content (50:50, F6) caused a significant increase in
mean Q48 (5.40 ± 0.39 lg/cm
2, P = 0.016) with no significant in-
crease in flux (6.19 ± 0.77 lg/cm2/h, P = 0.072).
In vitro release of Rh B from the three test NPs (F4–F6) at phys-
iological pH indicated enhanced drug release as a function of NPs
hydrophilicity (Fig. 6). Release profiles were characterized by lack
of burst effect and relatively low release rate indicating efficient
dye entrapment. Approximately 14.5%, 15.8%, and 17.2% of the
dye was released at 6 h from NPs prepared using PLGA with
copolymer ratio of 100:0 (F4), 75:25 (F5), and 50:50 (F6),
respectively.
3.2.1.3. Effect of NPs surface charge. FITC NPs with positive and neg-
ative zeta potential at 10% w/w loading (F10 and F12, respectively)
were used. Exposure of skin samples to negatively charged NPs re-
sulted in greater skin permeation of FITC despite the larger NPs
size (367.0 versus 122.0 nm for F10 and F12, respectively, Fig. 7
and Table 1). The mean Q48 and flux values for F12 NPs were
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0.24 ± 0.08 lg/cm2 and 0.35 ± 0.11 lg/cm2/h, respectively (Table
2). These corresponded to mean Q48 and flux values of
0.09 ± 0.01 lg/cm2 and 0.12 ± 0.02 lg/cm2/h for the positively
charged FITC NPs (F10), respectively. Differences between Q48
and flux values for F10 and F12 were statistically significant
(P < 0.05).
3.2.2. Effect of encapsulated dye-related variables on skin permeation
Fig. 8 shows permeation profiles for Rh B and FITC encapsulated
in 50:50 PLGA NPs at 10% w/w loading (F7 and F10, respectively,
Table 1). Both formulations had similar particulate properties in
terms of size (117.4 and 122.0 nm, respectively) and zeta potential
(57 mV). Poorer permeation of FITC was observed with a signifi-
cantly longer lag period (30 h) compared to Rh B NPs (6 h), sug-
gesting a different permeation mechanism. A statistically
significant 33.2-fold and 35.8-fold difference in Q48 and flux values,
respectively, was observed for Rh B compared to FITC. The Q48 and
flux values for Rh B were 2.99 ± 0.26 lg/cm2 and 4.29 ± 0.42 lg/
cm2/h, respectively. Significantly lower values (P < 0.05) for Q48
(0.09 ± 0.01 lg/cm2) and flux (0.12 ± 0.02 lg/cm2/h) were obtained
for FITC.
CLSM images of MN-treated porcine skin exposed to these two
NP formulations (F7 and F10) for 48 h were obtained for both ver-
tical sections (surface view of mechanically sectioned skin) and Z-
stacks to determine the depth of dye permeation (Fig. 9a–d). Rh B
and FITC NPs applied to the MN-treated skin surface infiltrated the
microchannels as evidenced by the red and green intense fluores-
cence in Fig. 9a and b, respectively, with deeper penetration of Rh
B. Individual NPs could not be visualized as their size was below
the resolution limit of the confocal microscope [32,33]. This is in
addition to deterioration of the resolution in real-case scenarios
when imaging biological specimens, skin in this case, in which
the light suffers several effects such as scattering [34]. While Rh
B diffused laterally as indicated by red fluorescence around micro-
channels and in deeper skin layers (Fig. 9a), FITC fluorescence was
mainly restricted to microchannels (Fig. 9b). Penetration depth
profiles (Z-stacks, Fig. 9c and d) showed deeper Rh B fluorescence,
thought to be a result of the released dye reaching a depth of
190 lm compared to 130 lm for FITC. Confocal imaging verified
the significantly lower skin permeability of nanoencapsulated FITC
compared to Rh B.
The effect of % initial loading on skin permeation of nanoencap-
sulated Rh B and FITC is shown in Fig. 10. Transdermal delivery of
Rh B increased significantly (P < 0.05) with the increase in dye
loading. For 5% Rh B loading (F8), Q48 and flux values were
1.78 ± 0.63 lg/cm2 and 2.53 ± 0.87 lg/cm2/h, respectively. Increas-
ing loading to 10% w/w (F7) and 20% w/w (F6) caused a significant
increase (P < 0.05) in both Q48 (2.99 ± 0.26 and 5.40 ± 0.39 lg/cm
2,
respectively) and flux (4.29 ± 0.42 and 6.19 ± 0.77 lg/cm2/h,
respectively). Differences between Q48 and flux values obtained
Fig. 1. Chemical structures of the two dyes selected for the study.
Fig. 2. Digital photographs of polymer MN arrays with 600 lm long MNs and a density of 121 MNs/array (a). SEM images of MN arrays showing top (b) and side (c) views. Bar
scales represent 1 mm.
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at 10% w/w and 20% w/w initial load were also statistically signif-
icant (P = 0.001 and 0.030, respectively). On the other hand,
increasing initial% FITC loading (5%, 10% and 20% w/w, F9, F10,
and F11, respectively, Table 1) led to reduced skin permeation
(Fig. 10 and Table 2). NP formulations F9, F10, and F11 showed
average Q48 values of 0.13 ± 0.04, 0.09 ± 0.01, and 0.06 ± 0.02 lg/
cm2, respectively (Table 2). This corresponded to an average flux
of 0.17 ± 0.05, 0.12 ± 0.02, and 0.09 ± 0.03 lg/cm2/h, respectively.
Differences between Q48 and flux values obtained at 5% w/w (F9)
and 20% w/w (F11) initial load were statistically significant
(P = 0.026 and 0.041, respectively). Notably, increasing the initial
FITC loading of NP stabilized with 1% w/v DMAB from 5% to 20%
w/w was associated with an increase in particle size with a higher
PDI for F11 and a decrease in zeta potential.
4. Discussion
The literature information provided proof of concept of en-
hanced transdermal delivery of drugs encapsulated in nanocarri-
ers, particularly liposomes [9] and polymeric NPs [10] across
MN-treated skin, promoting the transdermal delivery enhancing
effect of either approach used separately. A better mechanistic in-
sight is needed for optimization of this combined strategy for di-
verse drug delivery applications. At the outset, it could be
postulated that the flux of a nanoencapsulated drug across MN-
treated skin is a complex multifactorial process involving possible
in-skin transport of the nanocarrier and the released drug through
MN-created aqueous filled microchannels and deeper skin layers.
For biodegradable polymeric NPs, assuming lack of transdermal
delivery of the NPs across full thickness skin [10,22], MN/nanoen-
capsulation-mediated skin permeation may be hypothesized to in-
volve (a) translocation of drug-loaded NPs into MN-created
channels, generating drug-rich reservoirs mainly in the epidermis
and less densely in the dermis [22], a process influenced by MN ar-
ray characteristics and application [10] in addition to interaction of
NPs with the aqueous microchannel; (b) release of encapsulated
drug from NPs, a process taking place mainly in microchannels
[22] at a rate determined presumably by the physicochemical char-
acteristics of NPs, the encapsulated drug and the physiological
microenvironment; (c) diffusion of the released drug across hydro-
philic deeper skin layers in series. The latter step is a concentration
gradient-driven process, influenced by the drug molecular charac-
teristics and impeded by diffusional resistances of the microchan-
nels and the tissues beneath [20,25].
In a recent study, we reported on the effect of MN array character-
istics and application variables on the in vitro transdermal delivery of
Rh B encapsulated in PLGA NPs across full thickness MN-treated
porcine skin [10]. In the present work, we aimed at providing more
knowledge on the contribution of characteristics of nanocarrier
and encapsulated dye to MN-mediated transdermal delivery of
nanoencapsulated dyes. The skin model used was full thickness
Fig. 3. Representative TEM images of Rh B (F8, a) versus FITC (F9, b) PLGA 50:50 NPs at 5% w/w initial dye loading.
Table 2
Effect of formulation variables on the permeation of nanoencapsulated Rh B (F1–F8)
and FITC (F9–F12) across MN-treated full thickness porcine skin. Values are
mean ± SD (nP 3).
Dye Formula
code
Q48 (lg/cm
2) Steady state
flux (lg/cm2/h)
Rh B F1 0.50 ± 0.20 0.81 ± 0.28
F2 2.02 ± 0.11 2.83 ± 0.19
F3 2.49 ± 0.08 3.55 ± 0.09
F4 2.07 ± 0.19 2.90 ± 0.27
F5 2.92 ± 1.32 3.98 ± 1.62
F6 5.40 ± 0.39 6.19 ± 0.77
F7 2.99 ± 0.26 4.29 ± 0.42
F8 1.78 ± 0.63 2.53 ± 0.87
FITC F9 0.13 ± 0.04 0.17 ± 0.05
F10 0.09 ± 0.01 0.12 ± 0.02
F11 0.06 ± 0.02 0.09 ± 0.03
F12 0.24 ± 0.08 0.35 ± 0.11
Fig. 4. Effect of NPs size on Rh B permeation through MN-treated full thickness
porcine skin. Data points shown are mean ± SD (n = 3). SEM images of tested NP
formulations are shown on the right-hand side of the graph. Bar scale represents
200 nm.
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porcine ear skin (approximately 1164 lm-thick), a well-estab-
lished model representing full skin resistance and possessing char-
acteristics similar to those of human skin [35].
4.1. Effect of NPs-related variables on skin permeation of the
nanoencapsulated dye
Rh B or FITC-loaded NPs prepared at a relatively high emulsion
homogenization speed (15,000 rpm) with 1% w/v DMAB were
generally monodisperse with PDI < 0.2 and positively charged
due to adsorption of the cationic surfactant. Zeta potential values
exceeded 30 mV (36.1–67.6, Table 1), indicating physical stability
[36]. This was obvious in TEM images of sample NPs (Fig. 3). FITC
NPs prepared with PVA as emulsion stabilizer were negatively
charged (4.5 mV, Table 1).
4.1.1. Effect of NPs size
Reduction in the particle size of 20% w/w Rh B-loaded PLGA
50:50 NPs (F1–F3) in the range 422.3–155.2 nm (Table 1) resulted
in a significant increase in permeation of Rh B across MN-treated
skin (Fig. 4). For instance, a 2.7-fold reduction in the mean diame-
ter of F3 compared to F1 NPs led to a fivefold increase in Q48. It has
been demonstrated that permeation characteristics of a NP
through microchannels were significantly affected by NPs size
relative to the pore size [37]. As the width of MN-created micro-
channels is usually in the micron range [23], that is, significantly
larger than the size range of test NPs in the present study, and
NPs size dependence of Rh B skin permeation can be explained
by faster release of the encapsulated water soluble Rh B from
smaller size NPs with larger surface to volume ratio. Particle size
is a factor known to affect drug release from polymeric NPs [38].
Further, translocation of PLGA NPs across full thickness human
abdominal skin was shown to be NPs size dependent, despite the
larger microchannel size [22,23]. Combined findings suggest dee-
per and more extensive influx of smaller NPs through MN-created
channels leading to enhanced transdermal delivery of the water
soluble dye released at the deeper NPs deposition sites. Conse-
quently, factors related to particle size, such as wide particle size
distribution and NPs aggregation potential, may affect not only
NPs translocation across MN-treated skin but also transdermal
delivery of nanoencapsulated hydrophilic permeants. This should
be taken into consideration in the MN/nanoencapsulation modula-
tion of skin permeation.
Fig. 5. Effect of PLGA nanoparticles hydrophilicity on the permeation of Rh B
through MN-treated full thickness porcine skin. Data points shown are mean ± SD
(n = 3). SEM images of tested NP formulations are shown on the right-hand side of
the graph. Bar scale represents 200 nm.
Fig. 6. In vitro release profiles of Rh B loaded in PLGA NPs of different lactide to
glycolide copolymer ratio, (100:0, F4), (75:25, F5) and (50:50, F6) in PBS pH 7.4 at
37 C. Data points shown are mean ± SD (n = 3).
Fig. 7. Effect of NPs charge on the permeation of FITC through MN-treated full
thickness porcine skin. Data points shown are mean ± SD (n = 3).
Fig. 8. Comparative skin permeation profiles of Rh B (F7) and FITC (F10) NPs at 10%
w/w initial dye loading. Data points shown are mean ± SD (n = 3).
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4.1.2. Effect of NPs polymer composition and hydrophilicity
Increasing PLGA copolymer hydrophilicity by reducing the lac-
tide to glycolide ratio (Table 1) significantly enhanced transdermal
delivery of Rh B encapsulated in PLGA 50:50 NPs compared to
PLGA 75:25 and 100:0 NPs of similar size, PDI, and zeta potential
(Fig. 5 and Table 2). The results can be explained by greater com-
patibility of the more hydrophilic NPs with the aqueous milieu of
microchannels, which reduces translocation resistance, enabling
deeper penetration. The major diffusional resistance for a perme-
ant traversing the skin through microchannels lies in the dermal
layer [39]. Applying this principle to NPs means that reducing par-
ticle size and increasing hydrophilicity would enhance NPs move-
ment through hydrophilic microchannels. Additionally, NPs with
greater hydrophilicity will allow faster release of Rh B as a result
of improved wettability of NPs and interstitial fluid penetration
into the polymer matrix, a factor largely involved in drug release
from polymeric-based delivery systems [40]. This was verified by
the in vitro Rh B release data (Fig. 6). NPs with the three PLGA com-
positions (F4–F6) released Rh B at a hydrophilicity-dependent rate.
Possible involvement of PLGA degradation in release enhancement
is limited because of the relatively slow degradation rate of PLGA
NPs [10].
4.1.3. Effect on NPs surface charge
The effect of NPs charge type was investigated using 10% w/w
loaded FITC NPs with positive and negative zeta potential (F10
and F12, respectively, Table 1). Despite the larger size, negatively
charged NPs (F12, 367.0 nm, 4.5 mV) allowed significantly great-
er (P < 0.05) transdermal delivery of FITC compared to smaller NPs
bearing a positive charge (F10, 122.0 nm, 57 mV) (Fig. 7). A 2.7-fold
Fig. 9. Confocal images of vertical sections (a and b) and Z-stacks (c and d) of full thickness porcine skin treated with Rh B (F7) and FITC (F10) PLGA NPs, respectively. Bar
scales represent 50 lm (a and b) and 100 lm (c and d). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this
article.)
Fig. 10. Effect of NPs initial dye loading on cumulative permeation at 48 h (Q48)
through MN-treated full thickness porcine skin. Data points shown are mean ± SD
(n = 3). (For interpretation of the references to color in this figure legend, the reader
is referred to the web version of this article.)
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and 2.9-fold increases in Q48 and flux, respectively, could be ob-
served (Table 2). A similar lag time suggested no change in the
mechanism of drug transport. As porcine skin bears a net negative
charge at physiological pH [41], repulsion of negatively charged
NPs may reduce adsorption at its surface, driving NPs translocation
deeper into the microchannels and enhancing flux of released FITC.
These results are supported by the literature data [23] demonstrat-
ing faster diffusion of negatively charged fluorescent amine-modi-
fied polystyrene NPs (140 nm) through Isopore membrane, a
synthetic negatively charged membrane with cylindrical micro-
channels simulating microporated skin, compared to positively
charged NPs. Results were explained by electrostatic repulsion be-
tween the negatively charged NPs and Isopore membrane, pre-
venting surface binding and accelerating the flow of NPs through
aqueous channels.
Accordingly, surface charge type appears to have opposite ef-
fects on translocation of nanocarriers through microporated and
intact skin, the latter being enhanced by a positive zeta potential
that promotes electrostatic attraction with the negatively charged
skin, enhancing penetration [42–44]. Further studies are needed to
substantiate the NPs charge effects on permeation of nanoencapsu-
lated molecules across deeper skin layers.
4.2. Effect of encapsulated dye-related variables on permeation
PLGA NPs with similar properties (50:50 PLGA composition,
57.0 mV zeta potential, 10% w/w dye loading) and close particle
size (117.4 versus 122.0 nm for Rh B and FITC NPs, respectively, Ta-
ble 1) were used as nanocarrier for Rh B and FITC to assess the con-
tribution of encapsulated dye-related variables to skin permeation
across MN-treated skin. The two dyes have different molecular
characteristics in terms of chemical structure (a hydrophobic reac-
tive S@C@N substituent in FITC structure, Fig. 1), MW (479.02 ver-
sus 389.38 Da for Rh B and FITC, respectively), and saturated
solubility at physiological pH (0.99 versus 0.09 g/L for Rh B and
FITC, respectively) [25]. Despite the similarity of the nanocarrier
properties and a smaller MW (389.38 Da), significantly lower Q48
(97.0%) and flux (97.2%) values were obtained for FITC compared
to the more soluble and larger MW Rh B (Fig. 8 and Table 2). This
provided evidence for significant implication of the physicochem-
ical properties of encapsulated molecules, particularly solubility,
in the MN-mediated flux. Dye solubility would affect the release
and molecular diffusion steps of the hypothesized mechanism.
Higher solubility was reported to increase drug flux across MN-
treated skin since the dermis does not represent a distinct barrier
to hydrophilic drugs once the SC is bypassed [45]. For instance,
Stahl et al. [46] demonstrated enhanced MN-driven permeation
of the more hydrophilic permeants paracetamol and diclofenac
compared to the lipophilic drugs ibuprofen and ketoprofen, irre-
spective of molecular weights. Further, enhanced transdermal flux
was demonstrated for the water soluble hydrochloride form of nal-
trexone compared to the base [47] and the more soluble naltrex-
one glycolate compared to the hydrochloride salt [48]. The
significantly lower flux of FITC can be ascribed to poor solubility
due to the hydrophobic isothiocyanate substituent. This probably
resulted in slower release from NPs and saturation of the microen-
vironment, resulting in reduced concentration gradient and molec-
ular diffusion. In addition, the AN@C@S group was reported to
enhance reactivity of FITC toward nucleophiles such as amine
and sulfhydryl groups on proteins with the formation of covalent
dye-protein conjugates in vitro [49] and interaction with biomacro-
molecules in the human skin [50].
Difference in skin permeation of Rh B and FITC was confirmed
by confocal microscopic images obtained at 48 h post-skin treat-
ment (Fig. 9a–d). These showed deposition of fluorescent Rh B
and FITC NPs on the skin surface and probably superficial layers
of SC in addition to infiltration of NPs inside MN-created channels
(Fig. 9a and b, respectively), as reported previously [22]. Although
both dyes in the free form can penetrate intact skin to a limited ex-
tent [19,25,51] and MN-treated skin to a larger extent [10,25], con-
tribution of the free form of the dyes to the observed fluorescence
could be considered negligible in view of the limited dye release in
the small volume of fluids at the skin surface. Noteworthy, FITC
fluorescence was confined to microchannels (Fig. 9b), while diffuse
Rh B fluorescence was clearly observed around the pores and more
extensively in deeper skin layers (Fig. 9a). Depth penetration pro-
filing demonstrated relatively deep Rh B permeation with detect-
able red fluorescence at 190 lm. On the other hand, the green
FITC fluorescence was significantly reduced at a depth of 130 lm
and almost disappeared at 150 lm (Fig. 9c and d, respectively).
Difference in permeation of Rh B and FITC was further substan-
tiated by modulating the initial dye loading of NPs. While increas-
ing Rh B loading (F6–F8, Table 1) generally resulted in a
proportional significant increase in flux (Fig. 10), an increase in
FITC loading (F9–F11) had an opposite effect (Fig. 10). Results ver-
ified the role of solubility as a primary determinant of the flux of
small size permeants across hydrophilic deeper skin layers. Release
of a larger amount of the water soluble Rh B dye around the NPs
depot sites would build up a larger concentration gradient, the
main driving force for transport of soluble permeants [20]. Increas-
ing the concentration of hydrophilic permeants such as naltrexone
salts resulted in increased MN-mediated transdermal flux [48].
Although data for more drugs are needed, drug loading of nanocar-
riers is a formulation factor that can be modulated to control per-
meation of nanoencapsulated drugs with different molecular
characteristics through microporated skin for different skin deliv-
ery purposes.
Skin permeation data (Table 2) and CLSM imaging (Fig. 9) com-
bined with absence of NPs in the receiver compartment during the
study as confirmed by TEM provided sufficient evidence to suggest
that only the free dye released from NPs permeated skin layers to
the receiver compartment of the diffusion cell. It is worth mention-
ing that porcine skin barrier function proved to be maintained for
48 h using TEWL measurements [31] which was verified in this
study by the absence of NPs in the receiver compartment after
48 h. Further, data indicated that post-infiltration of NPs in MN-
created microchannels, a process affected largely by NPs character-
istics, skin permeation rates of the released dyes were determined
primarily by their molecular characteristics. The more hydrophilic
Rh B dye permeated MN-treated skin at a significantly greater rate
compared to the hydrophobic FITC dye of smaller MW, though
both were encapsulated in PLGA NPs with similar properties. Find-
ings tend to indicate that the MN/nanoencapsulation combined ap-
proach could be of benefit in enhancing transdermal delivery of
hydrophilic drugs and controlling dermal localization of hydropho-
bic drugs.
5. Conclusions
Mechanistic insights into transdermal drug delivery using the
dual microneedle (MN)/nanoencapsulation approach are provided
based on a systematic study of the skin permeation of nanoencap-
sulated Rh B and FITC across MN-treated porcine skin. Intuitively, a
mechanism hypothesized for this process should be based on inte-
grated information regarding the translocation of polymer NPs as a
charged colloidal system through micron-sized skin pathways and
the molecular diffusion of the released dye in hydrophilic deeper
skin tissues. Corroborated evidence obtained so far demonstrate
the impact of NP characteristics such as size relative to microchan-
nel dimensions, hydrophilicity, surface charge and potential NPs-
skin interaction on both the skin translocation of NPs and the
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transdermal delivery of nanoencapsulated drug models. In addition
to NPs composition and formulation attributes, molecular charac-
teristics of the released molecule exert a significant impact on skin
permeation. Poor solubility and potential interaction with skin
constituents were shown to override molecular weight as impedi-
ments to transdermal delivery of the nanoencapsulated dye.
Although further investigation with more drugs is needed to sup-
port findings of this study, it could be envisaged that synchronous
optimization of the characteristics of MN array, nanocarrier and
encapsulated agent would lead to improvement of the dual MN-
nanoencapsulation strategy as an effective approach for transder-
mal and localized delivery of nanoencapsulated agents for diverse
clinical applications such as enhanced vaccination and controlled
steroid administration for eczema or psoriasis.
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